Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GSK continues malaria work

GSK continues malaria work

3rd March 2008

GlaxoSmithKline (GSK) has received the results of two tests for new medicines for the treatment of malaria.

Through a joint project with Medicines for Malaria Venture, the firm has been working to create a new treatment for the disease.

Data from the phase III clinical trials assessing the use of Dacart, a fixed-dose combination of chlorproguanil, dapsone and artesunate, has recently been received by the firm, with results showing that the efficacy of the medicine when compared to Coartem, which is currently the first-line anti-malarial therapy in many countries.

Results showed there was a 94 per cent efficacy rate at 28 days, but there was a higher rate of reduction in haemoglobin levels than when Coartem was used.

Another new treatment, Lapdap, was also tested by the firm. This was created by GSK in collaboration with the World Health Organisation and the Department for International Development.

This test showed that there were also reductions in haemoglobin levels when Lapdap was used. As a result of these trials, GSK has opted to terminate development of Dacart and withdraw Lapdap.

Last month, GSK announced a series of price reductions for HIV medicines in the world’s poorest countries.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.